HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): James W. Long Stephen E. Clayson Bruce B. Reid Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Long, J. W. Articles by Renlund, D. G. Search for Related Content PubMed Articles by Long, J. W. Articles by Renlund, D. G. Related Collections Mechanical Circulatory Assistance Related Article

J Thorac Cardiovasc Surg 2008;135:1353-1361
© 2008 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Improving outcomes with long-term "destination" therapy using left ventricular assist devices

^a Utah Artificial Heart Program, LDS Hospital, Salt Lake City, Utah
^b Massachusetts General Hospital, Boston, Mass
^c Idaho Heart Institute, Idaho Falls, Idaho

Presented at the 31st Annual Meeting of the Western Thoracic Surgical Association, June 22–25, 2005, Victoria Conference Center and Fairmount Empress Hotel, Victoria, BC, Canada.

Received for publication April 3, 2006; revisions received August 16, 2006; accepted for publication September 5, 2006.

^_* Address for reprints: James W. Long, MD, PhD, Utah Artificial Heart Program, 8th Avenue and C Street, Salt Lake City, UT 84143. (Email: jimlong{at}ihc.com).

Objective: Destination therapy experience using long-term left ventricular assist devices was analyzed relative to the benchmark Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure trial to evaluate the potential for improving outcomes with this groundbreaking therapy for advanced heart failure.

Methods: The largest single-center experience with destination therapy in the United States (Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT) was retrospectively analyzed. All destination therapy recipients (n = 23) presented with chronic, advanced heart failure, meeting indications for destination therapy adopted from the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure trial. All received HeartMate left ventricular assist devices (Thoratec Corp, Pleasanton, Calif), with 87% receiving an improved XVE model. Advanced practice guidelines were implemented using a multidisciplinary approach. Survivals (Kaplan–Meier, log-rank analyses) and adverse events (Poisson regression) were compared with those of the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure left ventricular assist device group (n = 68).

Results: Survival in the destination therapy group was significantly increased (P = .007), with an overall reduction in mortality of 66%. The 2-year survival was 77% for destination therapy compared with 29% for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure left ventricular assist device group (P < .0001). The 1-year survival was 77% for destination therapy compared with the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure left ventricular assist device rate of 52% (P = .036). Adverse events decreased by 38% (3.90 per patient-year in the destination therapy group compared with the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure left ventricular assist device rate of 6.32). Factors related to severity of illness met Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure-like criteria for both groups.

Conclusions: This analysis provides evidence that long-term destination therapy can be improved well beyond the pioneering experience of the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure trial. With continued evolution of devices, management, and patient selection, outcomes approaching those of heart transplantation may be possible.

Related Article

Discussion
J. Thorac. Cardiovasc. Surg. 2008 135: 1360-1361. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				C. H. Zambroski, P. Combs, S. N. Cronin, and C. Pfeffer Edgar Allan Poe, "The Pit and the Pendulum," and Ventricular Assist Devices Crit. Care Nurse, December 1, 2009; 29(6): 29 - 39. [Full Text] [PDF]

				S. R. Wilson, M. M. Givertz, G. C. Stewart, and G. H. Mudge Jr Ventricular assist devices the challenges of outpatient management. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1647 - 1659. [Abstract] [Full Text] [PDF]

				E. A. Genovese, M. A. Dew, J. J. Teuteberg, M. A. Simon, J. Kay, M. P. Siegenthaler, J. K. Bhama, C. A. Bermudez, K. L. Lockard, S. Winowich, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann. Thorac. Surg., October 1, 2009; 88(4): 1162 - 1170. [Abstract] [Full Text] [PDF]

				H. J. Eisen and S. R. Hankins Continuous flow rotary left ventricular assist device: mechanical circulatory support 2.0. J. Am. Coll. Cardiol., July 21, 2009; 54(4): 322 - 324. [Full Text] [PDF]

				D. H. Adams, A. C. Anyanwu, J. Chikwe, and F. Filsoufi The Year in Cardiovascular Surgery J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2389 - 2403. [Full Text] [PDF]

				M. S. Slaughter Outcomes of Medicare Beneficiaries With Ventricular Assist Devices JAMA, April 22, 2009; 301(16): 1657 - 1658. [Full Text] [PDF]